Jair Alberto Arciniegas
Research Subjects
Jair Alberto Arciniegas has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Juan Manuel Reyes
Pfizer SAS, Bogotá, Colombia
3 shared publications Omar Escobar
Pfizer Inc
3 shared publicationsCarlos Fernando Mendoza
Pfizer Inc
2 shared publications- Carlos José Bello Gándara
Suramericana IPS—Sura, Medellín 050015, Antioquia, Colombia
2 shared publications Farley Johanna Gonzalez
Suramericana IPS - SURA, Medellín, Colombia
2 shared publications- Farley Johanna Gonzalez
Departamento de Química, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional, Av. Instituto Politécnico Nacional 2508, 07360 Ciudad de México, Mexico
2 shared publications
Latest Publications
- Open Access
Economic burden of Respiratory Syncytial Virus Infection in Colombia in 2019: A Cost-of-Illness Study
Background: Respiratory Syncytial Virus (RSV) is one of the leading causes of acute respiratory infections and severe cases can lead to hospitalization or death. The epidemiology and health resource utilization of RSV infection in Colombia is not well understood. Given the recent availability of new RSV preventatives, this study estimated the economic burden of RSV in Colombia. Methods: This cost-of-illness study employed a retrospective cohort design and bottom-up costing approach to estimate direct healthcare costs associated with RSV-related acute respiratory infections (ARI) across pediatric and adult populations. Administrative data from sentinel surveillance centers belonging to the National Epidemiological Surveillance System of the Colombian National Institute of Health, the database for the study of the Capitation Payment Unit database, and the Integrated Social Protection Information System were utilized to estimate RSV incidence, mortality, and healthcare costs. Costs were expressed in U.S. dollars (USD). Results: A total of 264,744 RSV-related healthcare consultations were identified in 2019. The highest incidence was among infants under one year (61.8 per 1,000), while general mortality was highest in adults ≥75 years (46.6 per 100,000), followed by infants (42.4 per 100,000). Total direct healthcare costs were estimated at $682.87 million (95% CI: $281.39–$1,084.35 million), with the largest share, contributed by individuals aged ≥15 years. Among infants under one year, ICU patients had the highest average cost ($3,619), and hospitalization accounted for 49% of total spending, followed by ICU care (29%) and medications (8%). Conclusions: RSV poses a significant economic burden on Colombia’s healthcare system. These findings support the need for targeted prevention strategies and efficient resource allocation. Future research should incorporate indirect costs and long-term impacts. Highlights: The study provides the first national-level estimate of the economic burden of RSV in Colombia using comprehensive administrative data. The highest incidence and healthcare costs are observed in infants under one year and adults over 75, highlighting the need for targeted prevention strategies. The findings can inform health policy and resource allocation decisions in Colombia’s universal healthcare system.
Open AccessEconomic burden of Respiratory Syncytial Virus Infection in Colombia in 2019: A Cost-of-Illness Study
Background: Respiratory Syncytial Virus (RSV) is one of the leading causes of acute respiratory infections and severe cases can lead to hospitalization or death. The epidemiology and health resource utilization of RSV infection in Colombia is not well understood. Given the recent availability of new RSV preventatives, this study estimated the economic burden of RSV in Colombia. Methods: This cost-of-illness study employed a retrospective cohort design and bottom-up costing approach to estimate direct healthcare costs associated with RSV-related acute respiratory infections (ARI) across pediatric and adult populations. Administrative data from sentinel surveillance centers belonging to the National Epidemiological Surveillance System of the Colombian National Institute of Health, the database for the study of the Capitation Payment Unit database, and the Integrated Social Protection Information System were utilized to estimate RSV incidence, mortality, and healthcare costs. Costs were expressed in U.S. dollars (USD). Results: A total of 264,744 RSV-related healthcare consultations were identified in 2019. The highest incidence was among infants under one year (61.8 per 1,000), while general mortality was highest in adults ≥75 years (46.6 per 100,000), followed by infants (42.4 per 100,000). Total direct healthcare costs were estimated at $682.87 million (95% CI: $281.39–$1,084.35 million), with the largest share, contributed by individuals aged ≥15 years. Among infants under one year, ICU patients had the highest average cost ($3,619), and hospitalization accounted for 49% of total spending, followed by ICU care (29%) and medications (8%). Conclusions: RSV poses a significant economic burden on Colombia’s healthcare system. These findings support the need for targeted prevention strategies and efficient resource allocation. Future research should incorporate indirect costs and long-term impacts. Highlights: The study provides the first national-level estimate of the economic burden of RSV in Colombia using comprehensive administrative data. The highest incidence and healthcare costs are observed in infants under one year and adults over 75, highlighting the need for targeted prevention strategies. The findings can inform health policy and resource allocation decisions in Colombia’s universal healthcare system.
- Open Access
- 22 May 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (6) , 146
Burden in Colombia of COVID-19 in Adults and the Associated Clinical Characteristics: A Retrospective Database Analysis
Studies on the burden of COVID-19 cases in Colombia have focused on specific populations and short timeframes. A retrospective observational study was conducted on adult patients aged 18 diagnosed with COVID-19 who received inpatient and/or outpatient medical care at a large health maintenance organization, to evaluate the burden of COVID-19 cases in Colombia (from March 2020 to January 2023) and associations with demographic and clinical characteristics. COVID-19 cases were identified with ICD-10 codes and confirmed by a laboratory test. The statistical analysis focused on descriptors of the frequency of events. A multivariate regression model was used to identify factors associated with severe conditions and death. Of the 953,661 cases detected, most cases (~79%) were mild or moderate (handled as outpatients). There were 20.1% (N = 191,260) severe cases and 0.9% (N = 8841) critical cases. Most COVID patients were unvaccinated (94.6%) and had, on average, one comorbidity. Hypertension (19.1%), immunocompromised condition (23.8%), mental health conditions (15%), obesity (10.8%), and cancer (11.2%) were the common prevalent comorbidities. The presence of comorbidity increased the risk of severe or critical COVID-19. COVID-19 cases were associated with the lack of vaccination and comorbidities. Effective vaccination strategies are needed to reduce the burden of COVID-19 in Colombia and, considering budgetary constraints, it is advisable to prioritize the elderly or populations with underlying conditions.
- 22 May 2025
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 10 (6) , 146
Open AccessBurden in Colombia of COVID-19 in Adults and the Associated Clinical Characteristics: A Retrospective Database Analysis
Studies on the burden of COVID-19 cases in Colombia have focused on specific populations and short timeframes. A retrospective observational study was conducted on adult patients aged 18 diagnosed with COVID-19 who received inpatient and/or outpatient medical care at a large health maintenance organization, to evaluate the burden of COVID-19 cases in Colombia (from March 2020 to January 2023) and associations with demographic and clinical characteristics. COVID-19 cases were identified with ICD-10 codes and confirmed by a laboratory test. The statistical analysis focused on descriptors of the frequency of events. A multivariate regression model was used to identify factors associated with severe conditions and death. Of the 953,661 cases detected, most cases (~79%) were mild or moderate (handled as outpatients). There were 20.1% (N = 191,260) severe cases and 0.9% (N = 8841) critical cases. Most COVID patients were unvaccinated (94.6%) and had, on average, one comorbidity. Hypertension (19.1%), immunocompromised condition (23.8%), mental health conditions (15%), obesity (10.8%), and cancer (11.2%) were the common prevalent comorbidities. The presence of comorbidity increased the risk of severe or critical COVID-19. COVID-19 cases were associated with the lack of vaccination and comorbidities. Effective vaccination strategies are needed to reduce the burden of COVID-19 in Colombia and, considering budgetary constraints, it is advisable to prioritize the elderly or populations with underlying conditions.
- Open Access
- 30 March 2025
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 24 (1) , 242-251
Estimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model
Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. This study evaluated the impact of various vaccination strategies with an adapted vaccine in Colombia. Using a previously published combined Markov-decision tree model adapted for the Colombia context, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality of life inputs derived from the published literature and national surveillance data. Scenario and sensitivity analyses were conducted to assess uncertainty. Compared to no vaccination, the vaccination strategy targeting older adults aged ≥65 years and the high-risk population was estimated to prevent 306,460 symptomatic cases, 5,200 hospitalizations, 3,381 deaths, and 39,454 lost QALYs, translating to total direct and societal cost savings of USD 70,840,305 and USD 128,918,995, respectively. These gains were further increased by expanding vaccination to additional age groups. Results were most sensitive to parameters for the attack rate and duration of protection. Implementing vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits in Colombia.
- 30 March 2025
- Published by Taylor & Francis in Expert Review of Vaccines
- Vol. 24 (1) , 242-251
Open AccessEstimating the potential public health and economic impact of vaccination strategies with an adapted vaccine in Colombia using a combined Markov-decision tree model
Using adapted COVID-19 vaccines targeting current variants in circulation is necessary for addressing the dynamic evolution of the SARS-CoV-2 virus and protecting against emerging variants. This study evaluated the impact of various vaccination strategies with an adapted vaccine in Colombia. Using a previously published combined Markov-decision tree model adapted for the Colombia context, this study estimated the outcomes of different vaccination strategies targeting various age and risk groups. The model used age-specific epidemiology, clinical, cost, and quality of life inputs derived from the published literature and national surveillance data. Scenario and sensitivity analyses were conducted to assess uncertainty. Compared to no vaccination, the vaccination strategy targeting older adults aged ≥65 years and the high-risk population was estimated to prevent 306,460 symptomatic cases, 5,200 hospitalizations, 3,381 deaths, and 39,454 lost QALYs, translating to total direct and societal cost savings of USD 70,840,305 and USD 128,918,995, respectively. These gains were further increased by expanding vaccination to additional age groups. Results were most sensitive to parameters for the attack rate and duration of protection. Implementing vaccination strategies targeting a broader age range with an adapted vaccine would result in considerable health and economic benefits in Colombia.
- Open Access
- 28 March 2025
- Published by BMJ in BMJ Paediatrics Open
- Vol. 9 (1) , e003243
Clinical characteristics and burden of COVID-19 in children and adolescents in Colombia: a retrospective database analysis
Background: The burden of COVID-19 infections has been extensively studied in some parts of the world. However, in emerging economies and particularly in Latin America and Colombia, research is still incomplete, especially in the paediatric population. This study aims to investigate the burden of COVID-19 infections in children and adolescents in Colombia to understand the burden and outcomes of COVID-19. Methods: This is a retrospective database analysis of 0–17-year-old persons diagnosed with COVID-19 and given inpatient or outpatient care at a large health maintenance organisation covering 10% of the entire population from March 2020 to January 2023. Cases were confirmed by International Classification of Diseases 10th Revision codes for COVID-19 and a lab test. The incidence rates of COVID-19 cases per 100 000 persons were calculated. With a multivariate logistic regression model adjusted for demographical and clinical characteristics, the factors related to developing severe or critical COVID-19 during the study period were identified. Results: Of the 76 376 COVID-19 cases included in the analysis, the mean age was 9.8 years, about 51.5% were male, 99.6% lived in urban areas and 98.9% were unvaccinated (76.9% of the cases occurred before the vaccination of this group began on 31 October 2021). Most cases (69 528, 91%) were classified as mild, 0.9% as moderate, 8% as severe and 0.1% as critical. The most prominent comorbidities were mental health-related conditions (18.9%), chronic lung disease (13.6%) and immunocompromised condition (10.6%). 28 deaths were observed, of which 22 had at least 1 comorbidity, the most frequent being chronic lung disease and mental health conditions. Conclusion: Nearly 1 in 5 cases of COVID-19 was documented in children with underlying medical conditions. Our findings underscore the need to target children with comorbidities.
- 28 March 2025
- Published by BMJ in BMJ Paediatrics Open
- Vol. 9 (1) , e003243
Open AccessClinical characteristics and burden of COVID-19 in children and adolescents in Colombia: a retrospective database analysis
Background: The burden of COVID-19 infections has been extensively studied in some parts of the world. However, in emerging economies and particularly in Latin America and Colombia, research is still incomplete, especially in the paediatric population. This study aims to investigate the burden of COVID-19 infections in children and adolescents in Colombia to understand the burden and outcomes of COVID-19. Methods: This is a retrospective database analysis of 0–17-year-old persons diagnosed with COVID-19 and given inpatient or outpatient care at a large health maintenance organisation covering 10% of the entire population from March 2020 to January 2023. Cases were confirmed by International Classification of Diseases 10th Revision codes for COVID-19 and a lab test. The incidence rates of COVID-19 cases per 100 000 persons were calculated. With a multivariate logistic regression model adjusted for demographical and clinical characteristics, the factors related to developing severe or critical COVID-19 during the study period were identified. Results: Of the 76 376 COVID-19 cases included in the analysis, the mean age was 9.8 years, about 51.5% were male, 99.6% lived in urban areas and 98.9% were unvaccinated (76.9% of the cases occurred before the vaccination of this group began on 31 October 2021). Most cases (69 528, 91%) were classified as mild, 0.9% as moderate, 8% as severe and 0.1% as critical. The most prominent comorbidities were mental health-related conditions (18.9%), chronic lung disease (13.6%) and immunocompromised condition (10.6%). 28 deaths were observed, of which 22 had at least 1 comorbidity, the most frequent being chronic lung disease and mental health conditions. Conclusion: Nearly 1 in 5 cases of COVID-19 was documented in children with underlying medical conditions. Our findings underscore the need to target children with comorbidities.
- Open Access
- 24 December 2024
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 25 (1) , 1-13
Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022
Background: To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured. Methods: This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years. Migraine patients were identified using the International Code Disease 10th version G43, and the diagnosis was confirmed by a neurologist. The first recorded migraine diagnosis was defined as the index date. Medical records, claim databases and other electronic databases from the HMO were used to determine the clinical characteristics, treatments, and health care services. Results: A total of 89,227 patients were included in the study. The mean follow-up period was 3.7 years (standard deviation 1.2). Most of them were women (84.9%). Many patients were first seen by a general practitioner (82.6%), and only 8.9% were first seen by a neurologist. The prevalence of migraine during follow-up was between 1.69 and 2.42 patients in 100 HMO affiliates in 2020, the year with the highest prevalence (2.42 [95% CI 2.41–2.44]), and the incidence ranged from 0.032 to 1.72 per 100 patient-year at risk of developing migraine. Hypertension (21.3%), arrythmia (4.1%) and structural heart disease (3.4%) were the most common cardiovascular diseases. The annual mean number of outpatient consultations in 2018 was 1.43 consultations per patient, which decreased to 0.68 in 2022. The most frequent treatments for acute events were nonsteroidal anti-inflammatory drugs (NSAIDs) (range 37-42%) in monotherapy, combinations of analgesics (range 14-35%), and corticosteroids (range 10-15%). Triptans were used in 4% of patients in the first medication record, reaching a maximum of 16% of patients. Among preventive treatments, beta-blockers (24-49%) and antiepileptics (29-41%) were the most common. Conclusion: The prevalence of migraine in Colombia according to health electronic databases was lower than that reported in previous studies conducted in the country. The treatment patterns for acute and preventive treatment of migraine follow the recommendations of different guidelines. Cardiovascular disease is relevant for the management of migraine.
- 24 December 2024
- Published by Springer Nature in The Journal of Headache and Pain
- Vol. 25 (1) , 1-13
Open AccessEpidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022
Background: To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured. Methods: This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years. Migraine patients were identified using the International Code Disease 10th version G43, and the diagnosis was confirmed by a neurologist. The first recorded migraine diagnosis was defined as the index date. Medical records, claim databases and other electronic databases from the HMO were used to determine the clinical characteristics, treatments, and health care services. Results: A total of 89,227 patients were included in the study. The mean follow-up period was 3.7 years (standard deviation 1.2). Most of them were women (84.9%). Many patients were first seen by a general practitioner (82.6%), and only 8.9% were first seen by a neurologist. The prevalence of migraine during follow-up was between 1.69 and 2.42 patients in 100 HMO affiliates in 2020, the year with the highest prevalence (2.42 [95% CI 2.41–2.44]), and the incidence ranged from 0.032 to 1.72 per 100 patient-year at risk of developing migraine. Hypertension (21.3%), arrythmia (4.1%) and structural heart disease (3.4%) were the most common cardiovascular diseases. The annual mean number of outpatient consultations in 2018 was 1.43 consultations per patient, which decreased to 0.68 in 2022. The most frequent treatments for acute events were nonsteroidal anti-inflammatory drugs (NSAIDs) (range 37-42%) in monotherapy, combinations of analgesics (range 14-35%), and corticosteroids (range 10-15%). Triptans were used in 4% of patients in the first medication record, reaching a maximum of 16% of patients. Among preventive treatments, beta-blockers (24-49%) and antiepileptics (29-41%) were the most common. Conclusion: The prevalence of migraine in Colombia according to health electronic databases was lower than that reported in previous studies conducted in the country. The treatment patterns for acute and preventive treatment of migraine follow the recommendations of different guidelines. Cardiovascular disease is relevant for the management of migraine.
- Open Access
- 9 August 2024
- Published by Springer Nature in Research Square
Epidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022.
Background To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured. Methods This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years. Migraine patients were identified using the International Code Disease 10th version G43, and the diagnosis was confirmed by a neurologist. The first recorded migraine diagnosis was defined as the index date. Medical records, claim databases and other electronic databases from the HMO were used to determine the clinical characteristics, treatments, and health care services. Results A total of 89,227 patients were included in the study. The mean follow-up period was 3.7 years (standard deviation 1.2). Most of them were women (84.9%). Many patients were first seen by a general practitioner (82.6%), and only 8.9% were first seen by a neurologist. The prevalence of migraine during follow-up was between 1.69 and 2.42 patients in 100 HMO affiliates in 2020, the year with the highest prevalence (2.42 [95% CI 2.41–2.44]), and the incidence ranged from 0.032 to 1.72 per 100 patient-year at risk of developing migraine. Hypertension (21.3%), arrythmia (4.1%) and structural heart disease (3.4%) were the most common cardiovascular diseases. The annual mean number of outpatient consultations in 2018 was 1.43 consultations per patient, which decreased to 0.68 in 2022. The most frequent treatments for acute events were nonsteroidal anti-inflammatory drugs (NSAIDs) (range 37%-42%) in monotherapy, combinations of analgesics (range 14%-35%), and corticosteroids (range 10%-15%). Triptans were used in 4% of patients in the first medication record, reaching a maximum of 16% of patients. Among preventive treatments, beta-blockers (24%-49%) and antiepileptics (29%-41%) were the most common. Conclusion The prevalence of migraine in Colombia according to health electronic databases was lower than that reported in previous studies conducted in the country. The treatment patterns for acute and preventive treatment of migraine follow the recommendations of different guidelines. Cardiovascular disease is relevant for the management of migraine.
- 9 August 2024
- Published by Springer Nature in Research Square
Open AccessEpidemiological, clinical characterization and treatment patterns of migraine patients in a Colombian cohort from 2018 to 2022.
Background To describe the epidemiology and clinical characteristics of migraine and the status of treatment in Colombia. Additionally, the use of health resources by patients was measured. Methods This was a non-interventional, retrospective, descriptive study conducted in one Colombian Health Management Organization (HMO) from 2018 to 2022 with a follow-up period of 5 years. Migraine patients were identified using the International Code Disease 10th version G43, and the diagnosis was confirmed by a neurologist. The first recorded migraine diagnosis was defined as the index date. Medical records, claim databases and other electronic databases from the HMO were used to determine the clinical characteristics, treatments, and health care services. Results A total of 89,227 patients were included in the study. The mean follow-up period was 3.7 years (standard deviation 1.2). Most of them were women (84.9%). Many patients were first seen by a general practitioner (82.6%), and only 8.9% were first seen by a neurologist. The prevalence of migraine during follow-up was between 1.69 and 2.42 patients in 100 HMO affiliates in 2020, the year with the highest prevalence (2.42 [95% CI 2.41–2.44]), and the incidence ranged from 0.032 to 1.72 per 100 patient-year at risk of developing migraine. Hypertension (21.3%), arrythmia (4.1%) and structural heart disease (3.4%) were the most common cardiovascular diseases. The annual mean number of outpatient consultations in 2018 was 1.43 consultations per patient, which decreased to 0.68 in 2022. The most frequent treatments for acute events were nonsteroidal anti-inflammatory drugs (NSAIDs) (range 37%-42%) in monotherapy, combinations of analgesics (range 14%-35%), and corticosteroids (range 10%-15%). Triptans were used in 4% of patients in the first medication record, reaching a maximum of 16% of patients. Among preventive treatments, beta-blockers (24%-49%) and antiepileptics (29%-41%) were the most common. Conclusion The prevalence of migraine in Colombia according to health electronic databases was lower than that reported in previous studies conducted in the country. The treatment patterns for acute and preventive treatment of migraine follow the recommendations of different guidelines. Cardiovascular disease is relevant for the management of migraine.
- 1 April 2016
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 45 (2) , 67-74
Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia
- 1 April 2016
- Published by Elsevier in Revista Colombiana de Psiquiatría
- Vol. 45 (2) , 67-74
Costo efectividad de los antipsicóticos en el tratamiento de mantenimiento de la esquizofrenia en Colombia
- 2 August 2015
- Published by Asociacion Colombiana de Medicina Interna in Acta Médica Colombiana
- Vol. 40 (2) , 118-124
Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia
Objetivo: Determinar la relación de costo-efectividad relativa de las estatinas entre sí en pacientes adultos con dislipidemia con predominio de hipercolesterolemia para la prevención de eventos cardiocerebrovasculares, en Colombia, desde la perspectiva del sistema de salud colombiano. Métodos: Se construyó un modelo de Markov con años de vida ajustados por calidad (AVAC) ganados como desenlace principal, tasa de descuento de 3 % tanto para costos como desenlaces, y cinco años de horizonte temporal. Probabilidades y costos se extrajeron de la literatura y de fuentes oficiales del país, respectivamente. El umbral de costo-efectividad fue tres veces el PIB per cápita de 2012. Se realizaron análisis de sensibilidad univariados, probabilísticos, umbral y curva de aceptabilidad. Resultados: El costo promedio del tratamiento con estatinas para un paciente con dislipidemia en 5 años es de $ 3.472.733.La ganancia en AVAC en rosuvastatina fue mayor con respecto a las otras estatinas, sin embargo, es la estrategia más costosa. La atorvastatina, que resultó segunda, es la más costo-efectiva. Conclusión: La intervención más costo-efectiva para pacientes con dislipidemia con predominio de hipercolesterolemia e indicación de manejo farmacológico con terapia moderada y alta con estatinas en Colombia es la atorvastatina.
- 2 August 2015
- Published by Asociacion Colombiana de Medicina Interna in Acta Médica Colombiana
- Vol. 40 (2) , 118-124
Costo-efectividad de las estatinas para el tratamiento de dislipidemia en Colombia
Objetivo: Determinar la relación de costo-efectividad relativa de las estatinas entre sí en pacientes adultos con dislipidemia con predominio de hipercolesterolemia para la prevención de eventos cardiocerebrovasculares, en Colombia, desde la perspectiva del sistema de salud colombiano. Métodos: Se construyó un modelo de Markov con años de vida ajustados por calidad (AVAC) ganados como desenlace principal, tasa de descuento de 3 % tanto para costos como desenlaces, y cinco años de horizonte temporal. Probabilidades y costos se extrajeron de la literatura y de fuentes oficiales del país, respectivamente. El umbral de costo-efectividad fue tres veces el PIB per cápita de 2012. Se realizaron análisis de sensibilidad univariados, probabilísticos, umbral y curva de aceptabilidad. Resultados: El costo promedio del tratamiento con estatinas para un paciente con dislipidemia en 5 años es de $ 3.472.733.La ganancia en AVAC en rosuvastatina fue mayor con respecto a las otras estatinas, sin embargo, es la estrategia más costosa. La atorvastatina, que resultó segunda, es la más costo-efectiva. Conclusión: La intervención más costo-efectiva para pacientes con dislipidemia con predominio de hipercolesterolemia e indicación de manejo farmacológico con terapia moderada y alta con estatinas en Colombia es la atorvastatina.
- Open Access
- 1 July 2014
- Published by Universidad del Norte in Investigación & Desarrollo
- Vol. 22 (2) , 212-230
Profile of corporate social responsibility managers of organizations linked to the global pact in Colombia
- 1 July 2014
- Published by Universidad del Norte in Investigación & Desarrollo
- Vol. 22 (2) , 212-230
Open AccessProfile of corporate social responsibility managers of organizations linked to the global pact in Colombia